NCT05226416

Brief Summary

Depersonalized multi-centered registry initiated to analyze dynamics of non-infectious diseases after SARS-CoV-2 infection in population of Eurasian adult patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3,554

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 1, 2022

Completed
6 days until next milestone

First Posted

Study publicly available on registry

February 7, 2022

Completed
14 days until next milestone

Study Start

First participant enrolled

February 21, 2022

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2022

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

April 21, 2023

Completed
Last Updated

May 9, 2023

Status Verified

May 1, 2023

Enrollment Period

1 month

First QC Date

February 1, 2022

Last Update Submit

May 6, 2023

Conditions

COVID-19Chronic Heart FailureDiabetes MellitusChronic Kidney DiseasesIschemic Heart DiseaseArrythmiaHypertensive Heart DiseaseOverweight and ObesityOncologyIschemic StrokeMyocardial InfarctionAtrial FibrillationDVTStrokeCopdAsthmaPulmonary EmbolismAnemiaMyocarditis

Keywords

covid-19ACTIVChronic Heart FailureIschemic Heart DiseaseHypertensive Heart DiseaseChronic Kidney DiseasesAtrial FibrillationMyocarditis

Outcome Measures

Primary Outcomes (2)

  • death for any cause

    rate of lethal outcomes

    From date of hospitalization until the date of first documented date of death from any cause, assessed up to 12 months

  • hospitalization for any cause

    rate of hospitalization for any cause

    12 months after discharge

Secondary Outcomes (2)

  • onset of any disease diagnosed 1 year after discharge

    1 year after discharge

  • rate of demand for medical care

    1 year after discharge

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Anonymized male and female patients over 18 years hospitalized with COVID-19 during the fourth wave of novel coronavirus disease.

You may qualify if:

  • Suspected or confirmed COVID-19

You may not qualify if:

  • Age under 18 years.
  • Refusal to be involved in study;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Eurasian Association of Therapists

Moscow, 101000, Russia

Location

MeSH Terms

Conditions

COVID-19Diabetes MellitusRenal Insufficiency, ChronicMyocardial IschemiaArrhythmias, CardiacOverweightObesityNeoplasmsIschemic StrokeMyocardial InfarctionAtrial FibrillationStrokePulmonary Disease, Chronic ObstructiveAsthmaPulmonary EmbolismAnemiaMyocarditis

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsHeart DiseasesCardiovascular DiseasesVascular DiseasesOvernutritionNutrition DisordersBody WeightSigns and SymptomsCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesInfarctionIschemiaNecrosisLung Diseases, ObstructiveBronchial DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEmbolismEmbolism and ThrombosisHematologic DiseasesHemic and Lymphatic DiseasesCardiomyopathies

Study Officials

  • Alexander Arutyunov, MD, PhD

    Eurasian Association of Therapists

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Organizational Committee

Study Record Dates

First Submitted

February 1, 2022

First Posted

February 7, 2022

Study Start

February 21, 2022

Primary Completion

March 31, 2022

Study Completion

April 21, 2023

Last Updated

May 9, 2023

Record last verified: 2023-05

Data Sharing

IPD Sharing
Will not share

Locations

RU(1)